[4 Society Joint]

Special Symposium
For the development of targeted radionuclide therapy in Japan

Fri. Oct 6, 2017 9:00 AM - 11:30 AM Conference Room 1 (Main Hall, Conference Center 1F)

Chair: Makoto Hosono(Institute of Advanced Clinical Medicine, Kindai University), Seigo Kinuya(Department of Nuclear Medicine, Kanazawa University), Hirofumi Fujii(Division of Functional Imaging, National Cancer Center Japan)

+Add all to schedule

[SS-01] Suggestion of problems in the domestic development and the solution to inner irradiation therapy

Takeshi Sasaki (Regional Medical Care Planning Divisivon, Labour and Welfare)

[SS-02] Advocacy for Targeted Radionuclide Therapy in Japan: How Grassroots Organizations can Influence Health Care Policy?

Kenichi Oi (Cancer Support Community Japan)

[SS-03] Radioisotope Therapy(RIT) Advocacy: Changing Cancer Care for pNET in Japan

Yoshiyuki Majima (NPO PanCAN Japan)

[SS-04] The regulation of unapproved drugs under the Radiation Hazards Prevention Act

Hirotaka Oku (Div. of Regulation for Radiation, Radiation Protection Dept., Nuclear Regulation Authority)

[SS-05] Development of targeted radionuclide therapy for clinical purpose

Noboru Oriuchi (Advanced Clinical Research Center, Fukushima Medical University)

[SS-06] JRIA’s role for the development of Radionuclide Therapy (for the future)

Nobutaka Nakamura (Japan Radioisotope Association)

[SS-07] Targeted Radioisotope Therapy using alpha-emitters - Future perspectives

Tatsuya Higashi (National Institute of Radiological Sciences)

Sessions

4 Society Joint Program » Special Symposium

Special Symposium
For the development of targeted radionuclide therapy in Japan

[SS-01] Suggestion of problems in the domestic development and the solution to inner irradiation therapy

[SS-02] Advocacy for Targeted Radionuclide Therapy in Japan: How Grassroots Organizations can Influence Health Care Policy?

[SS-03] Radioisotope Therapy(RIT) Advocacy: Changing Cancer Care for pNET in Japan

[SS-04] The regulation of unapproved drugs under the Radiation Hazards Prevention Act

[SS-05] Development of targeted radionuclide therapy for clinical purpose

[SS-06] JRIA’s role for the development of Radionuclide Therapy (for the future)

[SS-07] Targeted Radioisotope Therapy using alpha-emitters - Future perspectives

Authentication

Sessions

4 Society Joint Program » Special Symposium

Special SymposiumFor the development of targeted radionuclide therapy in Japan

[SS-01] Suggestion of problems in the domestic development and the solution to inner irradiation therapy

[SS-02] Advocacy for Targeted Radionuclide Therapy in Japan: How Grassroots Organizations can Influence Health Care Policy?

[SS-03] Radioisotope Therapy(RIT) Advocacy: Changing Cancer Care for pNET in Japan

[SS-04] The regulation of unapproved drugs under the Radiation Hazards Prevention Act

[SS-05] Development of targeted radionuclide therapy for clinical purpose

[SS-06] JRIA’s role for the development of Radionuclide Therapy (for the future)

[SS-07] Targeted Radioisotope Therapy using alpha-emitters - Future perspectives

Authentication

Special Symposium
For the development of targeted radionuclide therapy in Japan